NAPOLI 3 Trial: NALIRIFOX Results in Pancreatic Cancer

The NAPOLI 3 trial established a new first-line chemotherapy option for metastatic pancreatic cancer, showing that a four-drug combination called NALIRIFOX extended median overall survival to about 11 months compared with roughly 9 months for the previous standard regimen of gemcitabine plus nab-paclitaxel. That nearly two-month gain may sound modest in absolute terms, but for a cancer where five-year survival remains in the single digits, it represented a meaningful step forward and led to regulatory approvals in the United States and European Union.

What NAPOLI 3 Tested

NAPOLI 3 was a randomized, open-label, phase 3 trial enrolling 770 adults who had never received chemotherapy for metastatic pancreatic ductal adenocarcinoma, the most common and aggressive form of pancreatic cancer. Patients were assigned to one of two treatment arms: NALIRIFOX or gemcitabine plus nab-paclitaxel (often abbreviated Gem+NabP). NALIRIFOX is a four-drug cocktail combining liposomal irinotecan, fluorouracil, leucovorin, and oxaliplatin. Gem+NabP had been a go-to first-line option for over a decade, so it served as a solid benchmark.

The trial’s primary endpoint was overall survival, meaning how long patients lived from the time they started treatment. Progression-free survival, tumor response rates, and safety were also tracked. The study was international, enrolling patients across North America and the rest of the world, and results were first reported at a major oncology meeting in early 2023 before full publication in The Lancet.

The Path from NAPOLI-1 to NAPOLI 3

NAPOLI 3 did not emerge from nowhere. Its predecessor, the NAPOLI-1 trial, tested liposomal irinotecan combined with fluorouracil and leucovorin in patients whose pancreatic cancer had already progressed on gemcitabine-based therapy. That earlier trial showed a median overall survival of about 6.1 months with the combination versus 4.2 months with fluorouracil and leucovorin alone, and estimated one-year survival rates of 26% versus 16%.¹ Those results led to approval of liposomal irinotecan as a second-line treatment and set the stage for testing it earlier in the disease course, with oxaliplatin added to the mix.

The key ingredient distinguishing NALIRIFOX from older irinotecan-containing regimens is the liposomal formulation. Instead of delivering irinotecan as a conventional solution, the drug is encapsulated in tiny lipid-based particles. These nanoparticles tend to accumulate in tumor tissue because of the leaky blood vessels that tumors develop as they grow rapidly.² The practical effect is that the active drug lingers in the tumor longer and reaches higher concentrations there, while potentially reducing some of the toxicity seen with conventional irinotecan.

Survival Results

At a median follow-up of about 16 months, the trial’s primary endpoint was met. Median overall survival reached 11.1 months in the NALIRIFOX arm compared with 9.2 months for Gem+NabP, a difference that was statistically significant.³ Translated into relative terms, NALIRIFOX reduced the risk of death by about 17% compared with the standard regimen.

Progression-free survival, which measures how long before the cancer starts growing again, told a similar story. Median progression-free survival was 7.4 months with NALIRIFOX versus 5.6 months with Gem+NabP, amounting to a roughly 31% reduction in the risk of disease progression or death.⁴ For an oncologist evaluating whether to switch regimens, these numbers together paint a consistent picture: patients on NALIRIFOX stayed on treatment longer before their disease progressed, and they lived longer overall.

Tumor Shrinkage and How Long It Lasted

About 42% of patients on NALIRIFOX had their tumors shrink measurably, compared with 36% on Gem+NabP. That difference was not statistically significant on its own. What stood out more clearly was how long those responses lasted: the median duration of response was 7.3 months with NALIRIFOX versus 5.0 months with Gem+NabP, meaning patients who did respond kept benefiting for substantially longer.⁵ Complete responses, where the tumor disappears entirely on imaging, were extremely rare in both arms, occurring in less than 1% of patients. That is typical for metastatic pancreatic cancer, where a total disappearance of disease on chemotherapy alone is almost unheard of.

Side Effects

Both regimens are aggressive chemotherapy combinations, and both caused serious side effects. The most common severe (grade 3 or 4) problems in the NALIRIFOX group were low white blood cell counts, diarrhea, and low potassium. In the Gem+NabP group, the main severe toxicities were low white blood cell counts, anemia, and peripheral neuropathy, the tingling or numbness in hands and feet that nab-paclitaxel is known for.⁶

The difference matters because neuropathy from nab-paclitaxel tends to be cumulative. It can persist after treatment ends and interfere with daily tasks like buttoning a shirt or walking steadily. Diarrhea from NALIRIFOX, while disruptive and sometimes severe, is generally more manageable with medications and dose adjustments, and it tends to resolve more quickly. Treatment-related deaths occurred at the same low rate in both arms, roughly 2%, so neither regimen was clearly more dangerous in that regard.

Diarrhea management has become an active area of clinical focus for NALIRIFOX prescribers. Because diarrhea is a known dose-limiting side effect of irinotecan-based regimens, oncology teams have developed proactive strategies including anti-diarrheal medications and early dose modifications to keep patients on treatment. The trial itself allowed dose reductions and interruptions, which helped most patients continue therapy rather than stopping altogether.

Functional Status and Quality of Life

Survival in months only tells part of the story. How well patients feel during those months matters enormously, especially in a disease where treatment is palliative rather than curative. A dedicated analysis from NAPOLI 3 examined how long patients maintained their ability to carry out daily activities, measured by a standard performance status scale. Patients on NALIRIFOX took longer to deteriorate to a level where they could no longer care for themselves, with a roughly 28% reduction in the risk of that decline compared with Gem+NabP.⁷ This finding aligns with the survival advantage and suggests that the extra time NALIRIFOX provides is not time spent bedridden — patients stay functional longer.

Who Benefits

A question oncologists ask of any new regimen is whether the benefit holds across different patient groups or only shows up in a narrow slice of the trial population. Prespecified subgroup analyses from NAPOLI 3 showed that the survival improvement was generally consistent regardless of baseline performance status, geographic region, or whether patients had liver metastases.⁸ Liver metastases are present in the majority of metastatic pancreatic cancer patients and typically signal a worse prognosis, so the finding that NALIRIFOX still helped these patients is reassuring.

Older Patients

Age is always a concern in aggressive chemotherapy. A dedicated subgroup analysis split NAPOLI 3 patients into those under 70 and those 70 or older. In the NALIRIFOX arm, median overall survival was 11.7 months for younger patients and 10.0 months for older patients, while median progression-free survival was nearly identical at 7.4 and 7.3 months, respectively. The benefit of NALIRIFOX over Gem+NabP was preserved in the older subgroup, and there was no evidence of increased treatment-related toxicity in older patients compared with younger ones.⁹ In a disease that disproportionately strikes people in their sixties and seventies, this finding is particularly relevant.

Long-Term Survivors

Even in metastatic pancreatic cancer, a small fraction of patients substantially outlive the median. A final overall survival analysis from NAPOLI 3 characterized these long-term survivors and found that they tended to be slightly younger (median age around 61) and were more likely to have started treatment with good functional status. Interestingly, many of them still had features traditionally associated with poor outcomes: about two-thirds had liver metastases, and over half had three or more metastatic sites. Dose modifications and an otherwise favorable clinical profile seemed to help these patients stay on treatment long enough to derive maximum benefit.¹⁰

CA 19-9 as an Early Indicator

CA 19-9 is a protein that pancreatic tumors often shed into the bloodstream. It is widely used to monitor treatment response, but its value as a real-time readout during therapy has been debated. An analysis from NAPOLI 3 found that patients on NALIRIFOX whose CA 19-9 levels dropped at all by week 16 had strikingly better outcomes: a confirmed tumor response rate of about 65% versus 42% in those without a decline, and median overall survival of 15.4 months versus 8.4 months.¹¹ The implication is that tracking CA 19-9 during the first few months of NALIRIFOX could help oncologists identify early on which patients are benefiting most, potentially guiding decisions about whether to continue or switch therapy.

The UGT1A1 Gene and Dosing

Irinotecan, the backbone drug in NALIRIFOX, is broken down in the body by an enzyme encoded by the UGT1A1 gene. Some people carry a variant called UGT1A1*28 that slows this enzyme down, raising concerns that the drug might build up to toxic levels. In earlier studies of liposomal irinotecan in Asian cancer patients, those with two copies of reduced-function UGT1A1 variants had significantly higher rates of severe low white blood cell counts and diarrhea compared to those with normal enzyme activity.¹²

However, a dedicated pharmacogenomic analysis from NAPOLI 3 itself told a more reassuring story. Among the 39 NALIRIFOX patients who were homozygous for UGT1A1*28, rates of severe side effects and treatment discontinuation were similar to those in patients with other genotypes. Serious treatment-related events occurred in about a third of the homozygous group versus about 23% in others, but rates of dose reduction and treatment interruption did not differ meaningfully. The researchers concluded that full NALIRIFOX dosing can be used regardless of UGT1A1*28 status.¹³ This matters in practice because oncologists sometimes preemptively reduce irinotecan doses for patients with this gene variant. The NAPOLI 3 data suggest that preemptive dose reduction is unnecessary with the liposomal formulation, possibly because the encapsulated delivery changes how the drug is released and metabolized.

Regulatory Approval and Guideline Adoption

Based on the NAPOLI 3 results, the U.S. Food and Drug Administration approved NALIRIFOX in February 2024 as a first-line treatment for adults with metastatic pancreatic adenocarcinoma. The European Medicines Agency followed with its own approval. NALIRIFOX is now listed as a Category 1 preferred regimen in the National Comprehensive Cancer Network guidelines, which means the recommendation is backed by high-level evidence and uniform expert consensus.¹⁴ That puts NALIRIFOX alongside Gem+NabP and FOLFIRINOX as a top-tier option for first-line treatment.

Real-World Performance

Clinical trials enroll carefully selected patients who tend to be younger, fitter, and less burdened by other health conditions than the average person diagnosed with pancreatic cancer. A reasonable worry is that NALIRIFOX might not work as well in everyday clinical practice. Early real-world data, though still limited, has been encouraging. One analysis found that the efficacy outcomes seen in the trial could be reproduced in real-world patients, reinforcing the trial’s findings.¹⁵ A separate multicenter study from Thailand compared NALIRIFOX head to head with both modified FOLFIRINOX and Gem+NabP in a real-world setting using statistical matching to account for differences between patient groups.¹⁶ These early signals are helpful, though the body of real-world evidence will need to grow substantially before it can rival the trial data in confidence.

How NALIRIFOX Compares to FOLFIRINOX

The question many oncologists have asked since NAPOLI 3 was published is how NALIRIFOX stacks up not just against Gem+NabP, the trial comparator, but against FOLFIRINOX. FOLFIRINOX uses the same four drug families as NALIRIFOX but with conventional (non-liposomal) irinotecan. It has been a standard first-line regimen since around 2011, when it showed a substantial survival advantage over gemcitabine alone in fit patients. NAPOLI 3 did not compare NALIRIFOX directly to FOLFIRINOX, so any comparison requires indirect methods.

A comparative effectiveness analysis modeled the two regimens against each other, estimating that NALIRIFOX offered a progression-free survival of about 8.9 months versus 6.8 months for FOLFIRINOX, and a modest improvement in overall life-year gain. However, the monthly drug acquisition cost for NALIRIFOX was substantially higher, at roughly $13,600 compared with about $5,500 for FOLFIRINOX. That raw cost gap was partially offset by lower side-effect management expenses: monthly adverse-event costs were roughly $5,600 for NALIRIFOX versus about $15,500 for FOLFIRINOX, largely because FOLFIRINOX is associated with higher rates of hospitalizations for complications like febrile neutropenia.¹⁷ Whether these modeled differences hold up in real clinical practice is something the oncology community is still working out. Without a head-to-head randomized trial between NALIRIFOX and FOLFIRINOX, the choice between them often comes down to a clinician’s judgment about side-effect profiles, patient fitness, and logistical considerations like infusion schedules.

The Cost-Effectiveness Debate

NALIRIFOX is expensive, and two independent economic evaluations from a U.S. perspective have reached sobering conclusions about its value relative to its price tag. One analysis found that NALIRIFOX provided an additional 0.29 quality-adjusted life years over Gem+NabP, at an incremental cost-effectiveness ratio of roughly $206,000 per quality-adjusted life year, well above the commonly used $150,000 threshold.¹⁸ That study suggested NALIRIFOX could cross the cost-effectiveness line if the price of liposomal irinotecan dropped by about 15%.

A second economic evaluation reached a somewhat less unfavorable ratio, about $156,000 per quality-adjusted life year, and found that NALIRIFOX was cost-effective in roughly 46% of simulations at the $150,000 threshold.¹⁹ The discrepancy between the two studies reflects different modeling assumptions, but both point in the same direction: NALIRIFOX delivers a real clinical benefit, but the price of liposomal irinotecan pushes the value equation into uncertain territory. For health systems, insurers, and patients navigating out-of-pocket costs, the cost dimension is an unavoidable part of the decision. And in countries without well-resourced oncology budgets, FOLFIRINOX or Gem+NabP may remain the practical first-line options for years to come, regardless of NAPOLI 3’s results.

What Remains Unclear

For all that NAPOLI 3 resolved, several questions remain genuinely open. The trial did not include a FOLFIRINOX comparator arm, so the relative merits of NALIRIFOX versus modified FOLFIRINOX in a randomized setting are unknown. Ongoing real-world studies may eventually fill that gap, but without randomization, confounding factors will always cloud the picture somewhat. The trial also focused exclusively on metastatic disease. Whether NALIRIFOX has a role in earlier settings, such as locally advanced or borderline resectable pancreatic cancer, is being explored in separate studies but is not yet established. And while the pharmacogenomic analysis of UGT1A1*28 was reassuring, it was limited to one specific gene variant. Other genetic factors that influence drug metabolism or tumor sensitivity remain underexplored in this population. Pancreatic cancer remains one of the hardest cancers to treat, and NAPOLI 3 moved the needle in a meaningful way. The ongoing work is about figuring out exactly who benefits most and how to make the treatment accessible to everyone who could.